Fulgent Genetics

Historical price data

Fulgent Genetics has evolved from a genetic testing pioneer into a diversified precision medicine company, combining a comprehensive diagnostic business with an emerging therapeutic development arm. Its foundational technology platform supports an extensive menu of over 18,000 tests, including whole genome sequencing and rare disease panels, processed through a network of six accredited U.S. laboratories. The company's strategic direction involves merging diagnostic insights with therapeutic development, particularly in oncology, to create a closed-loop precision medicine model. Recent acquisitions, like Bako Diagnostics and StrataDx, further expand its capabilities in anatomic pathology and dermatopathology.

A proprietary platform integrating genetics, molecular biology, and computer science for clinical diagnostics, coupled with a novel nanoencapsulation and targeted therapy platform for developing cancer drug candidates.

Total raised: $40M

Fulgent competes in diagnostics with large reference labs (Quest, LabCorp) and specialized genomic firms (Myriad, Natera). Its move into therapeutics will eventually pit it against large pharma and biotech oncology players. Its differentiation lies in its vast, flexible test menu, proprietary technology, and unique strategy of combining diagnostics with therapeutic development.